Women in the second half of pregnancy, who were infected with genital mycoplasmas and who gave written informed consent, were randomly assigned to receive capsules of identical appearance containing erythromycin estolate, clindamycin hydrochloride, or a placebo for 6 weeks. Levels of serum glutamic oxalacetic transaminase (SGOT) were determined before and during treatment by a fluorometric method. All pretreatment levels of SGOT were normal (<41 units). Participants who received erythromycin estolate had significantly more abnormally elevated levels of SGOT (16/161, 9.9%) than did those who received clindamycin (4/168, 2.4%, P < 0.01) or those who received placebo (3/165, 1.8%, P < 0.01). Elevated levels of SGOT ranged from 44 to 130 U. Serum bilirubin levels were normal. Gamma-glutamyl transpeptidase activity was abnormal in six of six participants who had abnormal levels of SGOT while receiving erythromycin estolate. There were few associated symptoms, and all levels of SGOT returned to normal after cessation of treatment. The treatment of pregnant women with erythromycin estolate may be inadvisable.Erythromycin, a macrolide antibiotic produced by the actinomycete Streptomyces erythreus, has been used extensively in clinical medicine since its introdluction in 1952. Erythromycin base and its salts are not consistently absorbed from the gastrointestinal tract, presumably because they are destroyed by gastric acid. The only preparation of erythromycin that is well absorbed when given orally is the lauryl sulfate salt of the propionyl ester (propionyl erythromycin lauryl sulfate; erythromycin estolate [5]). The estolate is also the only form of erythromycin that has been associated with any reported hepatotoxicity. As reviewed by Braun (1), there have been reports of individuals who have developed hepatic toxicity in association with the administration of erythromycin estolate (8). Even when the propensity of erythromycin to produce hepatic toxicity has been considered to be established, it has been generally considered that this is an unusual idiosyncratic reaction (1, 5). The present report describes a group of pregnant women, over 9% of whom developed subclinical hepatotoxicity while receiving erythromycin estolate. Investigators in this laboratory have associated the genital mycoplasmas Mycoplasma hominis and Ureaplasma urealyticum (T-mycoplasmas) with birth weight. In one study (9), these organisms were found to be more prevalent among low-birth-weight infants than among infants of normal birth weight. In another study (3), women who were colonized with these organisms early in pregnancy gave birth to infants that weighed significantly less than infants whose mothers were not colonized. Earlier studies from this laboratory had found that non-bacteriuric pregnant women who were treated with a broad-spectrum antimicrobial agent gave birth to significantly fewer lowbirth-weight infants than did women who received a placebo (4; H. A. Elder, R. Smith, and E. H. Kass, Program Abstr. Intersci. Conf. Antimicrob. A...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.